Interferon for secondary progressive multiple sclerosis: a systematic review
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The human serine protease TMPRSS2 gene is involved in the priming of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins being one of the possible targets for COVID-19 therapy. TMPRSS2 gene is possibly co-expressed with SARS-CoV-2 cell receptor genes ACE2 and BSG, but only TMPRSS2 demonstrates tissue-specific expression in alveolar cells according to single cell RNA sequencing data. Our analysis of the structural variability of the TMPRSS2 gene based on genome-wide data of 76 human populations demonstrates that functionally significant missense mutation in exon 6/7 in TMPRSS2 gene, was found in many human populations in relatively high frequency, featuring region-specific distribution patterns. The frequency of the missense mutation encoded by the rs12329760, which previously was found to be associated with prostate cancer, is ranged between 10% and 63% being significantly higher in populations of Asian origin compared to European populations. In addition to SNPs, two copy numbers variants (CNV) were detected in the TMPRSS2 gene. Number of microRNAs have been predicted to regulate TMPRSS2 and BSG expression levels, but none of them is enriched in lung or respiratory tract cells. Several well studied drugs can downregulate the expression of TMPRSS2 in human cells, including Acetaminophen (Paracetamol) and Curcumin. Thus TMPRSS2 interaction with the SARS-CoV-2, its structural variability, gene-gene interactions, and expression regulation profiles, and pharmacogenomics properties characterize this gene as a potential target for COVID-19 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907 · cited 1×
“33 Such non-randomised studies are highly susceptible to bias, particularly because of differences between comparison groups (selection bias) and lack of study protocol (reporting bias) and their findings must be interpreted with caution.(35) The results of this review suggest that the effects of IFNb on relapse are i…”
BackgroundKappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Cited by
Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C. R. M., Clegg, S., Nielsen, C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62242-4 · Cited by 443
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed
Feinstein, A., Freeman, J., & Lo, A. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70231-5 · Cited by 281
Koffel, J. B., & Rethlefsen, M. L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163309 · Cited by 107
Cuprizone‐induced demyelination triggers a CD8‐pronounced T cell recruitment
Kaddatz, H., Joost, S., Nedelcu, J., Chrzanowski, U., Schmitz, C., Gingele, S., Gudi, V., Stangel, M., Zhan, J., Santrau, E., et al. (2021) · Glia · doi:10.1002/glia.23937 · Cited by 51
“Such a concept might explain why anti-inflammatory therapies, such as interferon beta (La Mantia et al., 2012; La Mantia et al., 2013) or fingolimod treatment (Lublin et al., 2016) are not effective during the progressive disease stage.”
Background
Metadata
- Authors
- Mantia, L. L., Vacchi, L., Rovaris, M., Di Pietrantonj, C., Ebers, G., Fredrikson, S., & Filippini, G.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2012-09-05
- Volume
- 84
- Issue
- 4
- Pages
- 420-426
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2139810922
- Cited by
- 61
- References
- 3
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon for secondary progressive multiple sclerosis: a systematic review. https://app.cochat.ai/papers/10.1136/jnnp-2012-303291
- The paper
- Mantia, L. L., Vacchi, L., Rovaris, M., Di Pietrantonj, C., Ebers, G., Fredrikson, S., & Filippini, G. (2013). Interferon for secondary progressive multiple sclerosis: a systematic review. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-303291
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.